Explore the words cloud of the InterTAU project. It provides you a very rough idea of what is the project "InterTAU" about.
The following table provides information about the project.
|Coordinator Country||Czech Republic [CZ]|
|Total cost||1˙062˙600 €|
|EC max contribution||1˙058˙000 € (100%)|
1. H2020-EU.1.3.3. (Stimulating innovation by means of cross-fertilisation of knowledge)
|Duration (year-month-day)||from 2020-01-01 to 2023-12-31|
Take a look of project's partnership.
|1||Masarykova univerzita||CZ (BRNO STRED)||coordinator||441˙600.00|
|2||AXON NEUROSCIENCE R&D SERVICES SE||SK (BRATISLAVA)||participant||464˙600.00|
|3||LATVIJAS ORGANISKAS SINTEZES INSTITUTS||LV (RIGA)||participant||128˙800.00|
|4||ROYAL COLLEGE OF SURGEONS IN IRELAND||IE (DUBLIN)||participant||23˙000.00|
|5||OREGON STATE UNIVERSITY||US (CORVALLIS)||partner||0.00|
|6||UNIVERSIDAD NACIONAL DE CUYO||AR (MENDOZA)||partner||0.00|
|7||UNIVERSITY HEALTH NETWORK||CA (TORONTO)||partner||0.00|
|8||UNIVERSITY OF PITTSBURGH||US (PITTSBURGH)||partner||0.00|
There is an enormous and unmet medical need to find efficient methods of prevention, diagnosis and disease-modifying therapies for tauopathies, including Alzheimer’s disease. The common molecular denominator of tauopathies are pathological forms of tau protein. Tau pathology relates to conformational changes during oligomerization and assembly resulting in toxicity. Given its role in the pathogenesis, conformationally altered and assembled tau would be a promising molecular target for disease-modifying therapy. However, the field is still lacking a deeper understanding of tau structural changes in the course of assembly and their inducers on the pathway towards the pathological forms of Tau; therefore, the pharma development is hampered. The main aim of the InterTau project is the detailed structural and biophysical characterization of tau protein and its variants in monomeric, oligomeric and fibrillar states relevant for AD and other tauopathies. The InterTAU consortium is composed of a clinical-stage biotech company pursuing development of anti-tau immunotherapy and academic partners with cutting-edge methodologies suitable for functional and structural characterization of the tau assembly pathway by solution and solid-state nuclear magnetic resonance (NMR), cryo-electron microscopy and cellular assays corroborated by bioinformatics. The mutual transfer of complementary expertise envisaged in the project will facilitate academic outcome and biotechnological development. Specific expertise will be transferred from three institutions in North America and one institution from Argentina. The results of InterTAU will be directly translated into innovation in pharmacological development through the non-academic partner. The platform for sharing knowledge will be a foundation of sustainable cooperation beyond the InterTau project.
|Project website||Websites, patent fillings, videos etc.||2020-04-03 12:46:44|
Take a look to the deliverables list in detail: detailed list of InterTAU deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "INTERTAU" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "INTERTAU" are provided by the European Opendata Portal: CORDIS opendata.
Nonsmooth Contact DynamicsRead More
Identifying Marginal Lands in Europe and strengthening their contribution potentialities in a CO2sequestration strategyRead More
Safe, Efficient and Integrated Indoor Robotic Fleet for Logistic Applications in Healthcare and Commercial SpacesRead More